Morgan Stanley analyst Michael Ulz maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report) yesterday and set a price target of $15.00. Discover top-rated stocks from highly ...

Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the Phase Ib/II trial than in preclinical models, according to William Blair ...

Tenaya Way. “We’re thinking it’s a possible threat,” the caller told police, according to a recording of the call shared with the Review-Journal. The person, whose name was redacted ...

(RTTNews) - Tenaya Therapeutics (TNYA) reported early data from the first cohort of patients in the MyPEAK-1 clinical trial of TN-201 gene therapy. TN-201 is being developed for the potential ...

SOUTH SAN FRANCISCO - Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology firm focusing on heart disease treatments with a market capitalization of $228 million, today shared promising initial ...

Here at TravelPulse, looking forward means we’re excited about new hotels and resorts opening next year! While this curated list of 25 of the coolest new hotels and resorts opening in 2025 isn’t ...

SOUTH SAN FRANCISCO - Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology firm focusing on heart disease treatments with a market capitalization of $228 million, today shared promising ...